| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
Purity: ≥98%
| Targets |
RU-58841 targets the androgen receptor (AR), a nuclear receptor that mediates the effects of androgens such as testosterone and dihydrotestosterone. As a specific androgen receptor antagonist, RU-58841 binds to AR and prevents androgen-induced receptor activation, thereby blocking the transcription of androgen-responsive genes. By inhibiting AR signaling in hair follicles, RU-58841 prevents androgen-induced miniaturization of hair follicles and promotes hair regrowth. The compound is a non-steroidal anti-androgen.
|
|---|---|
| ln Vitro |
In vitro, RU-58841 acts as a specific androgen receptor antagonist. It binds to the androgen receptor and blocks androgen-mediated signaling, preventing the transcription of androgen-responsive genes. The compound's ability to antagonize AR has been confirmed in cell-based assays measuring AR-mediated transcriptional activity. RU-58841 shows significant effects on hair regrowth in preclinical studies.
|
| ln Vivo |
In vivo, RU-58841 has a dramatic effect on hair regrowth. It has been studied for its potential in treating androgenetic alopecia (pattern hair loss) and other androgen-dependent conditions. However, specific in vivo efficacy data in animal models are not extensively detailed in the available literature. The compound is a research tool for studying androgen receptor signaling in hair follicles and other tissues.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for RU-58841 are radioligand binding assays using membrane preparations from cells expressing recombinant androgen receptors. The compound's binding affinity is determined by its ability to displace a labeled androgen receptor ligand such as [3H]testosterone or [3H]R1881. Functional assays such as reporter gene assays are used to measure the compound's antagonist activity at AR. The IC50 for inhibition of AR-mediated transcription is determined from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for RU-58841 are performed using cell lines expressing androgen receptors, such as LNCaP prostate cancer cells or dermal papilla cells. Cells are treated with varying concentrations of RU-58841, and AR-mediated transcriptional activity is assessed using luciferase reporter assays. Cell proliferation is measured using MTT assays. The compound's ability to antagonize androgen-induced signaling is confirmed by measuring the expression of AR target genes using quantitative PCR.
|
| Animal Protocol |
In vivo animal experiments for RU-58841 are conducted in animal models of androgenetic alopecia, such as the stump-tailed macaque or rodent models. Animals are administered RU-58841 topically or systemically, and hair regrowth is assessed by measuring hair follicle number, hair shaft diameter, and hair coverage. However, detailed protocols are not extensively documented in the available literature. The compound is a research tool and is not intended for human use.
|
| ADME/Pharmacokinetics |
RU-58841 has a molecular weight of 369.34 g/mol and a molecular formula of C17H18F3N3O3. It is a solid powder with a purity of ≥98%. The compound is soluble in DMSO at 40 mg/mL (108.3 mM). It should be stored as a powder at -20°C for up to 3 years or in solvent at -80°C for up to 1 year. Detailed pharmacokinetic parameters have not been extensively reported.
|
| Toxicity/Toxicokinetics |
The toxicological profile of RU-58841 has not been extensively characterized. As an androgen receptor antagonist, the compound may have potential endocrine-disrupting effects, including effects on reproductive function and bone metabolism. No significant toxicity has been reported in the available literature. Standard toxicology studies would be necessary to establish its safety profile. The compound is a research tool and is not intended for human use.
|
| References |
Castro GA, Ferreira LA. Novel vesicular and particulate drug delivery systems for topical treatment of acne. Expert Opin Drug Deliv. 2008 Jun;5(6):665-79. doi: 10.1517/17425247.5.6.665 . Review. PubMed PMID: 18532922.
|
| Additional Infomation |
RU-58841 is a specific androgen receptor antagonist with significant effects on hair regrowth. It is also known as PSK-3841 and HMR-3841. RU-58841 is a non-steroidal anti-androgen that has been studied for its potential in treating androgenetic alopecia (pattern hair loss) and other androgen-dependent conditions. It is a research compound and is not an approved drug.
|
| Molecular Formula |
C17H18F3N3O3
|
|---|---|
| Molecular Weight |
369.3442
|
| Exact Mass |
369.13
|
| Elemental Analysis |
C, 55.28; H, 4.91; F, 15.43; N, 11.38; O, 13.00
|
| CAS # |
154992-24-2
|
| Related CAS # |
154992-24-2
|
| PubChem CID |
132981
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
493.6±55.0 °C at 760 mmHg
|
| Flash Point |
252.3±31.5 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.560
|
| LogP |
1.39
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
26
|
| Complexity |
611
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(C1=C(C#N)C([H])=C([H])C(=C1[H])N1C(N(C([H])([H])C([H])([H])C([H])([H])C([H])([H])O[H])C(C([H])([H])[H])(C([H])([H])[H])C1=O)=O)(F)F
|
| InChi Key |
ARBYGDBJECGMGA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H18F3N3O3/c1-16(2)14(25)23(15(26)22(16)7-3-4-8-24)12-6-5-11(10-21)13(9-12)17(18,19)20/h5-6,9,24H,3-4,7-8H2,1-2H3
|
| Chemical Name |
4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
|
| Synonyms |
RU-58841; RU 58841; RU58841;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~270.75 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7075 mL | 13.5377 mL | 27.0753 mL | |
| 5 mM | 0.5415 mL | 2.7075 mL | 5.4151 mL | |
| 10 mM | 0.2708 mL | 1.3538 mL | 2.7075 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA